DocWire News Editors

DocwireNews

The Chronic Lymphocytic Leukemia (CLL) Comorbidity Index (CLL-CI), which examines endocrine, vascular, and upper-gastrointestinal conditions, reliably predicted survival and tolerance of ibrutinib therapy in patients with CLL, according to a study presented at the 62nd American Society of Hematology Annual Meeting &amp; Exposition.The researchers, led by Max J. Gordon, MD, of the MD Anderson Cancer Center in Houston, conducted a retrospective review of 339 patients with CLL who were treated with ibrutinib at nine academic centers between 2014 and 2019.At the time of starting ibrutinib, clinicians assessed vascular, endocrine, and upper-gastrointestinal organ systems. Each system received a score ranging from zero to three in order of increasing dysfunction severity, subsequently generating the CLL-CI score. A score of two or greater is considered high-risk.The median age of the patient population was 68 years. Approximately 71% of the patients were treated with ibrutinib in the relapsed/refractory setting. The median overall follow-up period was 23 months (range, 1-71 months).The majority of patients (60%) had a high-risk CLL-CI score. High CLL-CI score was associated with shortened event-free survival (hazard ratio [HR], 1.65; P=0.014) in a multivariate analysis adjusted for age, del(17p), and relapsed disease.Discontinuation of ibrutinib due to adverse events was more frequent in patients with a high CLL-CI score (25% vs. 14%; P=0.014). Additionally, a greater proportion of patients with a high CLL-CI score died because of disease progression (28% vs. 8%; P&lt;0.001).The researchers also found more rates of cardiovascular disease in the group of patients with a CLL-CI score of two or greater (37% vs. 16%; P&lt;0.001) as well as higher rates of hypertension with high CLL-CI (63% vs. 35%; P&lt;0.001).&ldquo;This result combined with the simplicity of scoring the CLL-CI makes it an attractive tool for clinical practice,&rdquo; the researchers wrote. &ldquo;CLL-CI needs to be explored prospectively in patients treated with ibrutinib and other targeted therapies.&rdquo;

Dr. Sadie Dobrozsi, Evolent

Rob Dillard

Genomics Tailors Breast Cancer Care, Cuts Unneeded Chemo

Genetics & Breast Cancer

Andrew Moreno

Extending Anticoagulation is Reasonable in Children with VTE, Data Suggest

Katie Kosko

DESTINY-Breast06: T-DXd Beats Chemo in HER2-Low HR+ mBC

Breast Cancer News

Latest News

Three-Variable CLL Comorbidity Index Predicts Survival, Tolerance of Ibrutinib in Patients with CLL

ASH Annual Meeting 2020

The Chronic Lymphocytic Leukemia (CLL) Comorbidity Index (CLL-CI), which examines endocrine, vascular, and upper-gastrointestinal conditions, reliably predicted survival and ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe